Search


Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency
CEO Jonathan Lim descrbies the profile of ERAS-0015 and the data the company has derived up to this point. A phase 3 study is planned in 1st line pancreatic cancer in the early part of 2027 and two in lung later in the year. He also discusses combinations, including with Erasca's own KRAS inhibitor. Coverage brought to you by
16 minutes ago






.png)
